Voice analysis platform Sonde Health raises $19.25M (MobiHealthNews):
AI-enabled voice technology platform Sonde Health announced it raised $19.25 million in a Series B funding round led by Partners Investment, bringing its total raise to $35.25 million … Sonde Health uses patented voice technology to detect various health conditions from biomarkers in a person’s voice, including analyzing respiratory fitness and detecting depression and anxiety.
The funding will help build out the company’s technology to detect additional health conditions, expand its current respiratory and mental health-monitoring technologies, and drive global commercial growth.
“Digital biomarkers are becoming a mainstay in healthcare. Today’s healthcare companies are realizing how vocal biomarkers can engage people earlier in their health. The data and insights found in voice can power health monitoring and patient stratification so issues can become apparent well before a costly medical event occurs,” David Liu, CEO of Sonde Health, said in a statement. “With voice and any listening device, accessible and effective health monitoring can be made available to the majority of the world.”
Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, has raised a $19.25 million Series B investment round … The company has raised $35.25 million in total and will use the funding to drive its global commercial growth, deepen its respiratory and mental health monitoring technologies, and build capabilities for additional health conditions.
Sonde licenses its platform to customers globally in two ways:
- Respiratory Fitness: Sonde’s platform can detect and monitor respiratory health conditions, like asthma, from 6 seconds of voice. Patients are engaging with Sonde’s respiratory fitness health checks 2+ times per week.
- Mental Fitness: Sonde’s platform can detect and monitor evidence of depression and anxiety from 30 seconds of voice. Patients are engaging with Sonde’s mental fitness health checks 3+ times per week.
Vocal Biomarker Development
- MCI, COPD, General Health: Sonde is developing novel vocal biomarkers using its proprietary “research-build-validation” methodology with clinical partners.
… GN Group will integrate Sonde’s Mental Fitness vocal biomarker into its hearing products. The company is already working with Sonde to develop an MCI vocal biomarker. Qualcomm, which has already integrated Sonde’s vocal biomarkers into its mobile device chipsets, has extended the relationship to include its wearable chipsets. Koye Pharmaceuticals, which had already engaged Sonde to develop a COPD vocal biomarker, has expanded the partnership to develop a novel mental health vocal biomarker for deployment in India.